knowledge -WSS

knowledge

author：leisure time 2025-09-28 23:47:57 - browse：1167

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Cord blood banking comes at a high cost to babies

WSS

JPM: CVS says Medicare Advantage patients are impacting profits

How to increase colonoscopy rates? Looks like an AI can help

See how much Covid

Innovation in antibiotics is ailing. 'Brain drain' may kill it

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

explore

knowledge

explore

Moonlake's readout produced a cash windfall. Risks remain

At ASCO, AstraZeneca reports strong data for breast cancer drug

Psychedelics group wrestles with new pharma identity

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

What does generative AI mean for health care? We asked experts

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Psychedelics group wrestles with new pharma identity

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Anesthesiologist group: stop taking Ozempic before surgery

Woman returns to dialysis after doctors remove transplanted pig kidney

focus

At ASCO, AstraZeneca reports strong data for breast cancer drug

NIH documents show early flaws of $1.6 billion long Covid program

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

NIH documents show early flaws of $1.6 billion long Covid program

White House finalizes ITC's import ban of latest Apple Watches

Feng Zhang, Grail founder join forces on new gene editing startup

hotspot

focus

Wikipedia

hotspot